GRALISE (gabapentin) by Almatica Pharma is analgesia, gabapentin prevents allodynia (pain-related behavior in response to a normally innocuous stimulus) and hyperalgesia (exaggerated response to painful stimuli). Approved for postherpetic neuralgia, partial seizure disorder, restless legs syndrome. First approved in 2011.
Drug data last refreshed 20h ago · AI intelligence enriched 3w ago
GRALISE is an extended-release oral tablet formulation of gabapentin, approved in 2011 for the treatment of postherpetic neuralgia (PHN). It works through a mechanism involving binding to voltage-activated calcium channel subunits and potentially antagonizing thrombospondin binding to α2δ-1 receptors, which prevents allodynia and hyperalgesia associated with neuropathic pain. Gabapentin does not act through GABA receptors or conventional neurotransmitter pathways despite its structural similarity to GABA. The product serves as a non-opioid option for chronic neuropathic pain management in the post-herpetic neuralgia indication.
analgesia, gabapentin prevents allodynia (pain-related behavior in response to a normally innocuous stimulus) and hyperalgesia (exaggerated response to painful stimuli). Gabapentin prevents pain-related responses in several models of neuropathic pain in rats and mice (e.g., spinal nerve ligation…
Worked on GRALISE at Almatica Pharma? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
High-dose Prophylactic Gabapentin (HOPE) vs. Placebo to Prevent Opioid Use for Oral Mucositis Pain During Concurrent Chemoradiation for Head and Neck Cancer
A Study on Ketoprofen Lysine Salt (KLS) + Gabapentin (GABA) vs KLS to Investigate Their Pharmacodynamic in Healthy Males
A Study of Oral Dosing of Gabapentin Enacarbil in Japanese Restless Legs Syndrome Patients
Efficacy of Gabapentin vs. Placebo for Adjuvant Pain Control Following Acute Rib Fractures
Prospective, Cross Over Gabapentin vs Amitriptyline Study on Patients Suffering From Masticatory Muscle Pain
Upgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/moGRALISE's mature, generic-competitive status creates limited career opportunities; roles would primarily focus on defending existing market share through managed care, formulary management, and patient support programs rather than growth-focused activities. Skills valued would include generic competitive strategy, payer relations, and cost-effectiveness argumentation. Currently, zero job openings are linked to this product, reflecting its status as a mature, declining-franchise asset.